URGN official logo URGN
URGN 3-star rating from Upturn Advisory
UroGen Pharma Ltd (URGN) company logo

UroGen Pharma Ltd (URGN)

UroGen Pharma Ltd (URGN) 3-star rating from Upturn Advisory
$22.98
Last Close (24-hour delay)
Profit since last BUY15.77%
upturn advisory logo
SELL
SELL since 1 day
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock price based on last close icon Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • 1Y
  • 1M
  • 1W

Upturn Advisory Summary

12/05/2025: URGN (3-star) is a SELL. SELL since 1 days. Simulated Profits (15.77%). Updated daily EoD!

Upturn Star Rating

Upturn 3 star rating for performance

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Number of Analysts

2 star rating from financial analysts

8 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $35.25

1 Year Target Price $35.25

Analysts Price Target For last 52 week
$35.25 Target price
52w Low $3.42
Current$22.98
52w High $30

Analysis of Past Performance

Type Stock
Historic Profit -7.07%
Avg. Invested days 26
Today’s Advisory SELL
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 12/05/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.08B USD
Price to earnings Ratio -
1Y Target Price 35.25
Price to earnings Ratio -
1Y Target Price 35.25
Volume (30-day avg) 8
Beta 1.23
52 Weeks Range 3.42 - 30.00
Updated Date 12/6/2025
52 Weeks Range 3.42 - 30.00
Updated Date 12/6/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.47

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-11-17
When -
Estimate -0.6434
Actual -0.69

Profitability

Profit Margin -170.59%
Operating Margin (TTM) -99.65%

Management Effectiveness

Return on Assets (TTM) -33.96%
Return on Equity (TTM) -1481.26%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1141115520
Price to Sales(TTM) 11.14
Enterprise Value 1141115520
Price to Sales(TTM) 11.14
Enterprise Value to Revenue 11.82
Enterprise Value to EBITDA -2.63
Shares Outstanding 46808892
Shares Floating 37059068
Shares Outstanding 46808892
Shares Floating 37059068
Percent Insiders 6.78
Percent Institutions 101.13

Icon representing Upturn AI-generated SWOT analysis summary Upturn AI SWOT

UroGen Pharma Ltd

UroGen Pharma Ltd(URGN) company logo displayed in Upturn AI summary

Company Overview

Company history and background logo History and Background

UroGen Pharma Ltd. is a biopharmaceutical company founded in 2004. It focuses on developing and commercializing novel solutions to treat urothelial cancers and other urological diseases. A significant milestone was the FDA approval of Jelmyto (mitomycin gel) in 2020, the first non-surgical treatment for low-grade upper tract urothelial cancer (LG UTUC). The company continues to expand its research and development efforts in the field of urology.

Company business area logo Core Business Areas

  • Uro-Oncology: Focuses on developing and commercializing treatments for urothelial cancers, primarily through its proprietary RTGel technology.
  • Specialty Urology: Encompasses the development of therapies for other urological conditions beyond cancer.

leadership logo Leadership and Structure

Liz Barrett is the CEO of UroGen Pharma. The company has a standard organizational structure with departments focused on research and development, clinical operations, commercialization, and finance.

Top Products and Market Share

Product Key Offerings logo Key Offerings

  • Jelmyto (mitomycin gel): Jelmyto is a reverse-thermal gel formulation of mitomycin approved for the treatment of low-grade upper tract urothelial cancer (LG UTUC). It provides a non-surgical option for patients. Revenue for 2023 was $87.4 million. Key competitors include conventional surgical treatments and other off-label intravesical chemotherapies. There is no readily available market share data.

Market Dynamics

industry overview logo Industry Overview

The uro-oncology market is growing due to the increasing incidence of bladder and upper tract urothelial cancers. There's a significant unmet need for non-surgical treatment options, driving innovation and market expansion.

Positioning

UroGen Pharma is positioned as a leader in non-surgical treatments for urothelial cancers, particularly with its Jelmyto product. Its RTGel technology provides a competitive advantage.

Total Addressable Market (TAM)

The TAM for UTUC treatment is estimated to be in the hundreds of millions of dollars annually, and the overall bladder cancer market is significantly larger. UroGen is positioned to capture a growing share of this market with Jelmyto.

Upturn SWOT Analysis

Strengths

  • FDA-approved product (Jelmyto)
  • Proprietary RTGel technology
  • First-mover advantage in non-surgical LG UTUC treatment
  • Strong clinical data supporting Jelmyto's efficacy

Weaknesses

  • Reliance on a single product (Jelmyto)
  • Relatively small commercial organization
  • Potential competition from emerging therapies
  • Dependence on reimbursement approvals for market access

Opportunities

  • Expansion of Jelmyto's indications
  • Development of new products using RTGel technology
  • Partnerships and collaborations with larger pharmaceutical companies
  • Geographic expansion into new markets

Threats

  • Competition from generic mitomycin formulations
  • Unfavorable changes in reimbursement policies
  • Clinical trial failures for pipeline products
  • Regulatory hurdles for new product approvals

Competitors and Market Share

Key competitor logo Key Competitors

  • BCRX
  • ADXS
  • CLVS

Competitive Landscape

UroGen's advantage lies in its novel RTGel technology and first-mover advantage with Jelmyto. Disadvantages include reliance on a single product and competition from larger, more established pharmaceutical companies.

Growth Trajectory and Initiatives

Historical Growth: UroGen's growth has been driven by the commercialization of Jelmyto. Revenue has increased steadily since its launch.

Future Projections: Analysts project continued revenue growth for Jelmyto as it gains wider acceptance and market penetration. Future growth is also dependent on the success of the company's pipeline programs.

Recent Initiatives: UroGen is focused on expanding the use of Jelmyto and advancing its pipeline programs, including UGN-102 (mitomycin reverse thermal gel) for LG-UTUC.

Summary

UroGen Pharma is a biopharmaceutical company with a focus on uro-oncology, particularly the treatment of low-grade upper tract urothelial cancer (LG UTUC). Jelmyto is driving revenue, but the company is not yet profitable. The company holds a promising pipeline program. Further growth depends on successful execution of pipeline and positive developments in reimbursement policies.

Similar Stocks

Sources and Disclaimers

Data Sources:

  • UroGen Pharma Ltd. Investor Relations
  • SEC Filings
  • Analyst Reports

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Market share data is estimated.

Information icon for Upturn AI Summarization accuracy disclaimer AI Summarization is directionally correct and might not be accurate.

Information icon for Upturn AI Summarization data freshness disclaimer Summarized information shown could be a few years old and not current.

Information icon warning about Upturn AI Fundamental Rating based on potentially old data Fundamental Rating based on AI could be based on old data.

Information icon warning about potential inaccuracies or hallucinations in Upturn AI-generated summaries AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About UroGen Pharma Ltd

Exchange NASDAQ
Headquaters Princeton, NJ, United States
IPO Launch date 2017-05-04
President, CEO & Director Ms. Elizabeth A. Barrett
Sector Healthcare
Industry Biotechnology
Full time employees 287
Full time employees 287

UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.